Zilico

Manchester

Zilico designs and manufactures the next generation of medical diagnostic devices that remove subjectivity, increase accuracy and deliver results in real-timefor clinical screening programmes, globally.

Zilicos flagship product, ZedScan, can differentiate between normal, pre-cancerous and cancerous cells in the cervix, providing a real-time diagnosis for cervical cancer. The higher accuracy ZedScan offers, detects more disease and allows clinicians to better manage patients than the current standard of care.

Withseveral regulatory approvals (Europe, Canada, Australia and Israel), ZedScan is already in routine use in hospitals delivering improved patient outcomes and economic benefits to hospitals.

Since launch in 2006, the company has raised approximately 5.7 million in equity from angel investors as well as from a leading lifescienceVC, for the product development, regulatory process, CE mark and product trials of the ZedScan.

The company is now completing its latestfunding round of 1.7 million of which 1.2 million has already been raised from new and existing shareholders.VentureFounders among other investors is supporting the company with its500,000 EIS eligible capital raise at a pre-money valuation of 8.4 million fully diluted.

Proceeds will be usedto further drive commercial adoption of ZedScanand expand its product development into other clinical areas.

Zilico is led by Sameer Kothari, former CEO of Plasso Technology (acquired by Becton Dickinson), and a strong board of directors and medical advisors.

ZedScan has been awarded a number of accolades including its pivotal clinical trial data which was awarded the Best Scientific Presentation at the American Society of Colposcopy and Cervical Pathology (ASCCP).

The post Zilico designs and manufactures the next generation of medical diagnostic devices appeared first on iCrowdNewswire.

Source: Icrowdnewswire